Efficacy and safety of vitamin D supplementation in hospitalized COVID-19 pediatric patients: A randomized controlled trial

Jessie Zurita-Cruz, Jeffry Fonseca-Tenorio, Miguel Villasís-Keever, Mardia López-Alarcón, Israel Parra-Ortega, Briceida López-Martínez, Guadalupe Miranda-Novales, Jessie Zurita-Cruz, Jeffry Fonseca-Tenorio, Miguel Villasís-Keever, Mardia López-Alarcón, Israel Parra-Ortega, Briceida López-Martínez, Guadalupe Miranda-Novales

Abstract

Background: Some studies suggested that adequate levels of vitamin D (VD) decrease the risk of severe COVID-19. Information about the effectiveness of VD supplementation in children is scarce.

Objective: To assess the efficacy and safety of VD supplementation compared to the standard of care in hospitalized children with COVID-19.

Patients and methods: An open-label randomized controlled single-blind clinical trial was carried out. We included patients from 1 month to 17 years, with moderate COVID-19, who required hospitalization and supplemental oxygen. They were randomized into two groups: the VD group, which received doses of 1,000 (children < 1 year) or 2,000 IU/day (from 1 to 17 years) and the group without VD (control). The outcome variables were the progression of oxygen requirement, the development of complications, and death.

Statistical analysis: For comparison between groups, we used the chi-squared test or Fisher's exact test and the Mann-Whitney U test. Absolute risk reduction (ARR) and the number needed to treat (NNT) were calculated. p ≤ 0.05 was considered statistically significant.

Results: From 24 March 2020 to 31 March 2021, 87 patients were eligible to participate in the trial; 45 patients were randomized: 20 to the VD group and 25 to the control group. There was no difference in general characteristics at baseline, including serum VD levels (median 13.8 ng/ml in the VD group and 11.4 ng/ml in the control group).

Outcomes: 2/20 (10%) in the VD group vs. 9/25 (36%) in the control group progressed to a superior ventilation modality (p = 0.10); one patient in the VD group died (5%) compared to 6 (24%) patients in the control group (p = 0.23). ARR was 26% (95% CI 8.8 to 60.2%) and NNT was 3 (2 to 11) for progression and ARR was 19% (95% CI -3.9 to 42.8%) and NNT was 6 (2 to 26) for death. None of the patients receiving VD had adverse effects. The trial was stopped for ethical reasons; since after receiving the results of the basal VD values, none of the patients had normal levels.

Conclusion: In this trial, VD supplementation in pediatric patients seems to decrease the risk of COVID-19 progression and death. More studies are needed to confirm these findings.

Clinical trial registration: This protocol was registered on ClinicalTrials.gov with the registration number NCT04502667.

Keywords: COVID-19; Latin America; Pediatrics; SARS-CoV-2; children; mortality; vitamin D.

Copyright © 2022 Zurita-Cruz, Fonseca-Tenorio, Villasís-Keever, López-Alarcón, Parra-Ortega, López-Martínez and Miranda-Novales.

Figures

Figure 1
Figure 1
CONSORT flow diagram.
Figure 2
Figure 2
Comparison of basal and seventh day serum concentrations of fibrinogen (a), D-dimer (b), and C-reactive protein (c), and in the control and vitamin D supplementation groups.

References

    1. COVID 19 en Pediatría: Valoración Crítica de la Evidencia . Comité/Grupo de Pediatría Basada en la Evidencia de la AEP y AEPap. (2022). Available online at (accesed March 10, 2022).
    1. Venturini E, Montagnani C, Garazzino S, Donà D, Pierantoni L, Lo Vecchio A, et al. . Treatment of children with COVID-19: update of the Italian society of pediatric infectious diseases position paper. Ital J Pediatr. (2021) 47:199. 10.1186/s13052-021-01132-2
    1. Wang Z, Zhao S, Tang Y, Wang Z, Shi Q, Dang X, et al. . Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review. Eur J Pediatr. (2022) 181:2135–46. 10.1007/s00431-022-04388-w
    1. Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. . A living WHO guideline on drugs for COVID-19. BMJ. (2020) 370:m3379. 10.1136/bmj.m3379
    1. La Tessa A, Motisi MA, Marseglia GL, Cardinale F, Licari A, Manti S, et al. . Use of remdesivir in children with COVID-19 infection: a quick narrative review. Acta Biomed. (2021) 92:e2021524. 10.23750/abm.v92iS7.12396
    1. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. (2015) 282:20143085. 10.1098/rspb.2014.3085
    1. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. (2020) 267:1260–63. 10.1126/science.abb2507
    1. Liu C, He Y, Liu L, Li F, Shi Y. Children with COVID-19 behaving milder may challenge the public policies: a systematic review and meta-analysis. BMC Pediatr. (2020) 20:410. 10.1186/s12887-020-02316-1
    1. González-García N, Castilla-Peón MF, Solórzano Santos F, Jiménez-Juárez RN, Martínez Bustamante ME, Minero Hibert MA, et al. . COVID-19 incidence and mortality by age strata and comorbidities in Mexico city: a focus in the pediatric population. Front Public Health. (2021) 9:738423. 10.3389/fpubh.2021.738423
    1. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol. (2012) 76:315–25. 10.1111/j.1365-2265.2011.04261.x
    1. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. (2007) 449:419–26. 10.1038/nature06175
    1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. (1998) 392:245–52. 10.1038/32588
    1. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, et al. . 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol. (2007) 178:145–53. 10.4049/jimmunol.178.1.145
    1. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. (2000) 374:334–8. 10.1006/abbi.1999.1605
    1. Mailhot G, White JH. Vitamin D and immunity in infants and children. Nutrients. (2020) 12:1233. 10.3390/nu12051233
    1. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. . Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. (2004) 173:2909–12. 10.4049/jimmunol.173.5.2909
    1. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. . Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE. (2011) 6:e25333. 10.1371/journal.pone.0025333
    1. Li-Ng M, Aloia JF, Pollack S, Cunha BA, Mikhail M, Yeh J, et al. . A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. (2009) 137:1396–404. 10.1017/S0950268809002404
    1. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. (2010) 91:1255–60. 10.3945/ajcn.2009.29094
    1. Grant CC, Kaur S, Waymouth E, Mitchell EA, Scragg R, Ekeroma A, et al. . Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial. Acta Paediatr. (2015) 104:396–404. 10.1111/apa.12819
    1. Somnath SH, Biswal N, Chandrasekaran V, Jagadisan B, Bobby Z. Therapeutic effect of vitamin D in acute lower respiratory infection: a randomized controlled trial. Clin Nutr ESPEN. (2017) 20:24–8. 10.1016/j.clnesp.2017.02.003
    1. Xiao L, Xing C, Yang Z, Xu S, Wang M, Du H, et al. . Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials. Br J Nutr. (2015) 114:1026–34. 10.1017/S000711451500207X
    1. Petrelli F, Luciani A, Perego G, Dognini G, Colombelli PL, Ghidini A. Therapeutic and prognostic role of vitamin D for COVID-19 infection: a systematic review and meta-analysis of 43 observational studies. J Steroid Biochem Mol Biol. (2021) 211:105883. 10.1016/j.jsbmb.2021.105883
    1. Liu N, Sun J, Wang X, Zhang T, Zhao M, Li H. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis. Int J Infect Dis. (2021) 104:58–64. 10.1016/j.ijid.2020.12.077
    1. Campi I, Gennari L, Merlotti D, Mingiano C, Frosali A, Giovanelli L, et al. . Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect Dis. (2021) 21:566. 10.1186/s12879-021-06281-7
    1. Chiodini I, Gatti D, Soranna D, Merlotti D, Mingiano C, Fassio A, et al. . Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Health. (2021) 9:736665. 10.3389/fpubh.2021.736665
    1. Güven M, Gültekin H. The effect of high-dose parenteral vitamin D3 on COVID-19-related inhospital mortality in critical COVID-19 patients during intensive care unit admission: an observational cohort study. Eur J Clin Nutr. (2021) 75:1383–8. 10.1038/s41430-021-00984-5
    1. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. . Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol. (2020) 203:105751. 10.1016/j.jsbmb.2020.105751
    1. Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. . Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J. (2022) 98:87–90. 10.1136/postgradmedj-2020-139065
    1. Esposito S, Marchetti F, Lanari M, Caramelli F, De Fanti A., Vergine G, et al. . COVID-19 management in the pediatric age: consensus document of the COVID-19 working group in paediatrics of the Emilia-Romagna region (RE-CO-Ped), Italy. Int J Environ Res Public Health. (2021) 18:3919. 10.3390/ijerph18083919
    1. Van den Ouweland JM, Beijers AM, Demacker PN, van Daal H. Measurement of 25-OH-vitamin D in human serum using liquid chromatography tandem-mass spectrometry with comparison to radioimmunoassay and automated immunoassay. J Chromatogr B Analyt Technol Life Sci. (2010) 878:1163–8. 10.1016/j.jchromb.2010.03.035
    1. Dirección, General de Epidemiología,. Lineamiento Estandarizado de la Vigilancia Epidemiológica y por Laboratorio de la Enfermedad Respiratoria Viral . Available online at: (accessed May 4, 2022).
    1. Ramirez-Sandoval JC, Castillos-Ávalos VJ, Paz-Cortés A, Santillan-Ceron A, Hernandez-Jimenez S, Mehta R, et al. . Very low vitamin D levels are a strong independent predictor of mortality in hospitalized patients with severe COVID-19. Arch Med Res. (2022) 53:215–22. 10.1016/j.arcmed.2021.09.006
    1. Rustecka A, Maret J, Drab A, Leszczyńska M, Tomaszewska A, Lipińska-Opałka A, et al. . The impact of COVID-19 pandemic during 2020-2021 on the vitamin D serum levels in the paediatric population in Warsaw, Poland. Nutrients. (2021) 13:1990. 10.3390/nu13061990
    1. Kang HM, Jeong DC, Suh BK, Ahn MB. The impact of the Coronavirus disease-2019 pandemic on childhood obesity and vitamin D status. J Korean Med Sci. (2021) 36:e21. 10.3346/jkms.2021.36.e21
    1. Meoli M, Muggli F, Lava SAG, Bianchetti MG, Agostoni C, Kocher C, et al. . Vitamin D status in adolescents during COVID-19 pandemic: a cross-sectional comparative study. Nutrients. (2021) 13:1467. 10.3390/nu13051467
    1. Alpcan A, Tursun S, Kandur Y. Vitamin D levels in children with COVID-19: a report from Turkey. Epidemiol Infect. (2021) 149:e180. 10.1017/S0950268821001825
    1. Kumar R, Rathi H, Haq A, Wimalawansa SJ, Sharma A. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. Virus Res. (2021) 292:198235. 10.1016/j.virusres.2020.198235
    1. Karonova TL, Chernikova AT, Golovatyuk KA, Bykova ES, Grant WB, Kalinina OV, et al. . Vitamin D intake may reduce SARS-CoV-2 infection morbidity in health care workers. Nutrients. (2022) 14:505. 10.3390/nu14030505
    1. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. . Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. (2021) 325:1053–60. 10.1001/jama.2020.26848
    1. Nogues X, Ovejero D, Pineda-Moncusí M, Bouillon R, Arenas D, Pascual J, et al. . Calcifediol treatment and COVID-19-related outcomes. J Clin Endocrinol Metab. (2021) 106:e4017–27. 10.1210/clinem/dgab405
    1. Oscanoa TJ, Amado J, Vidal X, Laird E, Ghashut RA, Romero-Ortuno R. The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration - a metaanalysis. Adv Respir Med. (2021) 89:145–57. 10.5603/ARM.a2021.0037
    1. Varikasuvu SR, Thangappazham B, Vykunta A, Duggina P, Manne M, Raj H, Aloori S. COVID-19 and vitamin D (Co-VIVID study): a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. (2022) 20:907–13. 10.1101/2021.08.22.21262216
    1. Shah K, Varna VP, Pandya A, Saxena D. Low vitamin D levels and prognosis in a COVID-19 pediatric population: a systematic review. QJM. (2021) 114:447–53. 10.1093/qjmed/hcab202
    1. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. . Evaluation, treatment, and prevention of Vitamin D deficiency: and endocrine society clinical practice guideline. J Clin Endocrinol Metabol. (2011) 96:1911–30. 10.1210/jc.2011-0385
    1. Briceno Noriega D, Savelkoul HFJ. Vitamin D: a potential mitigation tool for the endemic stage of the COVID-19 pandemic? Front Public Health. (2022)10:888168. 10.3389/fpubh.2022.888168

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever